Momeclir Adverse Reactions

Treatment-related adverse events reported in clinical studies for allergic rhinitis in adult and adolescent patients are shown as follows (Table 1). (See Table 1.)

Click on icon to see table/diagram/image

Epistaxis was generally self-limiting and mild in severity, and occurred at higher incidence compared to placebo (5%), but at a comparable or lower incidence when compared to the active control nasal corticosteroids studied (up to 15%). The incidence of all other effects was comparable with that of placebo.
In the pediatric population, the incidence of adverse events, e.g., epistaxis (6%), headache (3%), nasal irritation (2%) and sneezing (2%) was comparable with that of placebo.
In patients treated for nasal polyposis, the overall incidence of adverse events was comparable to placebo and similar to that observed for patients with allergic rhinitis.
Treatment-related adverse events in 1% of patients in clinical studies for polyposis are shown as follows (Table 2). (See Table 2.)

Click on icon to see table/diagram/image

In patients treated for acute rhinosinusitis, the incidence of epistaxis for Mometasone furoate (Momeclir) Nasal spray suspension was 3.3% vs. 2.6% for placebo and similar to that observed for patients treated with allergic rhinitis.
Rarely, immediate hypersensitivity reactions, including bronchospasm and dyspnea, may occur after intranasal administration of Mometasone furoate. Very rarely, anaphylaxis and angioedema have been reported.
Disturbances of taste and smell have been reported very rarely.
As with other intranasal corticosteroids rare cases of nasal septum perforation have been reported.
Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods.
Rare cases of glaucoma, increased intraocular pressure and/or cataracts have been reported with the use of intranasal corticosteroids.